eplerenone and Bone-Diseases--Metabolic

Although the mineralocorticoid receptor (MR) is expressed in osteoblasts and osteocytes and frequently co-localizes with the glucocorticoid receptors (GR), its pathophysiological functions in bone remain elusive. We report here that pharmacologic inhibition of MR function with eplerenone resulted in increased bone mass, with stimulation of bone formation and suppression of resorption, while specific genetic deletion of MR in osteoblast lineage cells had no effect. Further, treatment with eplerenone as well as specific deletion of MR in osteocytes ameliorated the cortical bone thinning caused by slow-release prednisolone pellets. Thus, MR may be involved in the deleterious effects of glucocorticoid excess on cortical bone.

Topics: Animals; Bone and Bones; Bone Diseases, Metabolic; Eplerenone; Glucocorticoids; Mice; Mice, Inbred Strains; Mineralocorticoid Receptor Antagonists; Osteocytes; Osteogenesis; Prednisone; Receptors, Mineralocorticoid; Spironolactone